June 18, 2025
Biomea Fusion Announces Proposed Public Offering of Securities
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity…
Pharmaceuticals, Biotechnology and Life Sciences
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity…
CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics…
Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhDDottie Caplan promoted to Executive Vice President, Patient…
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in…
Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to…
Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed…
All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June…
Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel…
The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration…
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial…